印度格列卫价格 新版（The price of new India Gleevec）.docVIP

印度格列卫价格 新版（The price of new India Gleevec） Generic name: imatinib mesylate (produced by NATCO, India) is called VEENAT. Commonly known as: India Gleevec) Name: VEENAT English Name: Imatinib Mesylate Capsules specifications: 120 bottle / Pinyin: Jiahuangsuan Yimatini Jiaonang VEENAT for India NATCO company, received FDA approval, not in Chinese, so in China for illegal drugs, the only function of Encyclopedia notes. The following is the introduction of Gleevec introduction, VEENAT is not introduced, India is commonly known as the unsuspecting gleevec. [1] Greve (imatinib mesylate) is a new generation of targeted anticancer drugs that inhibit the platelet derived growth factor (PDGF) receptor protein kinase. Greve is one of the most effective of all antineoplastic drugs. Greve was effective in the treatment of newly diagnosed chronic myelogenous leukemia (CML) by more than 94%, and 76% of patients received cytological remission. Greve (imatinib mesylate) packed 120 tablets per bottle, each containing 119.45 mg imatinib mesylate, equivalent to 100mg imatinib free base. Medicine in white polyethylene bottles. The results show that the phase three clinical trial of Gleevec on newly diagnosed chronic myelogenous leukemia (CML) treatment efficiency more than 94%, and 76% of the patients can be relieved of the cytological effective rate, accelerated phase and blast crisis also reached 71% and 31% respectively. The effective rate of Greve on gastrointestinal stromal tumors is as high as 67%. Indication： Greve (imatinib mesylate) is used to treat newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in adults in chronic phase. Greve (imatinib mesylate) for the treatment of Philadelphia chromosome positive in blastic phase and accelerated phase chronic myelogenous leukemia, imatinib mesylate for the treatment of interferon has also treated in the chronic phase of chronic myelogenous leukemia. Greve (imatinib mesylate) is also used to treat relapse